



APPROPRIATE USE CHECKLIST:

BUPRENORPHINE-CONTAINING TRANSMUCOSAL PRODUCTS FOR OPIOID DEPENDENCE

This checklist is a useful reminder of the safe use conditions and monitoring requirements for prescribing buprenorphine-containing transmucosal products for opioid dependence.

Requirements to address during each patient's appointment include:

- understanding and reinforcement of safe use conditions
- the importance of psychosocial counseling
- screening and monitoring patients to determine progress towards treatment goals

If a patient continues to abuse various drugs or is unresponsive to treatment, including psychosocial intervention, it is important that you assess the need to refer the patient to a specialist and/or a more intensive behavioral treatment environment.

Additional resource: Providers Clinical Support System for Medication Assisted Treatment: (<https://pcssnow.org>)

Use this checklist or other means (e.g. electronic health record) during the induction period to document that the safe use conditions listed have been completed. After the induction period, use the maintenance checklist on the next page.

INDUCTION CHECKLIST		
ASSESSMENT TO ENSURE APPROPRIATE USE		NOTES
Date:		
CHECK	INDUCTION	
<input type="checkbox"/> Appropriate Diagnostic Criteria	Verified patient meets appropriate diagnostic criteria for opioid dependence	
<input type="checkbox"/> Prescription Drug Monitoring	Checked patient's prescription profile in the Prescription Drug Monitoring Program (PDMP) , as appropriate	
<input type="checkbox"/> Opioids/CNS Depressants	<ul style="list-style-type: none"> • Reviewed all medications (e.g., benzodiazepines, other opioids, CNS depressants) and illicit substances to assess for appropriateness of co-prescribing 	
<input type="checkbox"/> Risks and Side Effects	<p>Discussed the risks and side effects described in professional labeling and Medication Guide with patient including</p> <ul style="list-style-type: none"> • potential for abuse and misuse • potential for fatal additive effects with benzodiazepines and other CNS depressants, including alcohol 	
<input type="checkbox"/> Conditions of Safe Storage	<p>Explained or reviewed conditions of safe storage of medication</p> <ul style="list-style-type: none"> • Reinforced importance of secure storage and keeping the medication out of the sight and reach of all others, especially children 	
<input type="checkbox"/> Co-prescription of Naloxone if Appropriate	Strongly considered prescribing naloxone because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose	
<input type="checkbox"/> Naloxone for Opioid Overdose	Discussed with patient and caregiver the importance of having access to naloxone if there are household members (including children), or other close contacts at risk for accidental ingestion or opioid overdose.	
<input type="checkbox"/> Induction Doses	Provided induction doses under appropriate medical supervision	
<input type="checkbox"/> Limited Amount of Medication	<p>Prescribed limited amount of medication at first visit</p> <ul style="list-style-type: none"> • enough to last until next visit 	
<input type="checkbox"/> Professional Counseling	Assessed participation in professional counseling and support services	
<input type="checkbox"/> Scheduled Next Visit	<p>Scheduled next visit at interval commensurate with patient stability</p> <ul style="list-style-type: none"> • Weekly, or more frequent, visits are recommended for the first month 	

Use this checklist or other means (e.g. electronic health record) to document that the safe use conditions listed have been completed for visits following the induction period.

MAINTENANCE CHECKLIST		
ASSESSMENT TO ENSURE APPROPRIATE USE		NOTES
Date:		
CHECK	MAINTENANCE	
<input type="checkbox"/> Co-prescription of Naloxone if Appropriate	Strongly considered prescribing naloxone because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose	
<input type="checkbox"/> Naloxone for Opioid Overdose	Discussed with patient and caregiver the importance of having access to naloxone if there are household members (including children), or other close contacts at risk for accidental ingestion or opioid overdose.	
<input type="checkbox"/> Take Medication As Prescribed	Assessed and encouraged patient to take medication as prescribed	
<input type="checkbox"/> Pill/Film Count/Dose Reconciliation	<ul style="list-style-type: none"> Consider pill/film count/dose reconciliation 	
<input type="checkbox"/> Appropriateness of Dosage	Assessed appropriateness of dosage <ul style="list-style-type: none"> Buprenorphine combined with naloxone is recommended for maintenance: Buprenorphine/Naloxone SL tablet and film (Suboxone® and its generic equivalents): doses ranging from 12 mg to 16 mg of buprenorphine are recommended for maintenance Buprenorphine and naloxone sublingual film (Cassipa®): a target dose of 16 mg of buprenorphine is recommended for maintenance Buprenorphine/Naloxone SL tablet (Zubsolv®): a target dose of 11.4 mg buprenorphine is recommended for maintenance Buprenorphine/Naloxone Buccal Film (Bunavail®): a target dose of 8.4 mg of buprenorphine is recommended for maintenance Doses higher than this should be an exception The need for higher doses should be carefully evaluated 	
<input type="checkbox"/> Urine Drug Screens	Conducted urine drug screens as appropriate to monitor compliance with prescribed buprenorphine treatment plan or ascertain use of illicit substances	
<input type="checkbox"/> Prescription Drug Monitoring Program	Checked patient's prescription profile in the Prescription Drug Monitoring Program (PDMP) , as appropriate	
<input type="checkbox"/> Professional Counseling	Assessed participation in professional counseling and support services	
<input type="checkbox"/> Benefits vs. Risks	Assessed whether benefits of treatment with buprenorphine-containing products outweigh risks associated with buprenorphine-containing products	
<input type="checkbox"/> Progress Toward Treatment Goals	Assessed whether patient is making adequate progress toward treatment goals <ul style="list-style-type: none"> Considered results of urine drug screens as part of the evidence of the patient complying with the treatment program Considered referral to more intensive forms of treatment for patients not making progress 	
<input type="checkbox"/> Scheduled Next Visit	Scheduled next visit at interval commensurate with patient stability <ul style="list-style-type: none"> Weekly, or more frequent, visits are recommended for the first month 	